Investeringsforeningen Sparinvest - ophævelse af suspension
Under henvisning til Nasdaq Copenhagens regler for udstedere af investeringsbeviser skal ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg hermed på vegne af de berørte afdelinger i Investeringsforeningen Sparinvest offentliggøre, at der igen kan foretages beregning af indre værdier for de pågældende afdelinger. De indre værdier er indberettet til Nasdaq Copenhagen. Suspension af handel med de berørte afdelinger ophæves hermed.
Der er tale om følgende afdelinger:
ISIN | Afdelingsnavn | Orderbookcode |
DK0010014778 | Sparinvest Mix Aktier KL A | SPIMAKLA |
DK0010079631 | Sparinv Value Aktier KL A | SPIVAKLA |
DK0010304856 | Sparinv Value Emerging Markets KL A | SPIVEMKLA |
DK0060012896 | Sparinv Momentum Aktier Akk. KL A | SPIMAAKLA |
DK0010297464 | Sparindex INDEX DJSI World KL | SPIDJWKL |
DK0060300762 | Sparindex INDEX Emerging Markets KL | SPIEMIKL |
DK0060031847 | Sparindex INDEX Globale Akt Min Risk KL | SPIGLAMRIKL |
DK0010298272 | Sparindex INDEX USA Growth KL | SPIUSGKL |
DK0010298355 | Sparindex INDEX USA Small Cap KL | SPIUSSKL |
DK0010298439 | Sparindex INDEX USA Value KL | SPIUSVKL |
DK0061294048 | Sparinvest Bæredygtige Aktier KL A | SPIBDA |
DK0061293826 | Sparinvest Globale Fokusaktier KL A | SPIGFA |
DK0061551892 | Sparinvest Mix Maksimum Risiko KL A | SPIMMRIA |
DK0061551546 | Sparinvest Bæredygtige Value Aktier KL A | SPIBDVAA |
DK0060623189 | Sparinv Mix Lav Risiko KL A | SPIMLRKLA |
DK0060623262 | Sparinv Mix Mellem Risiko KL A | SPIMMRKLA |
DK0060623346 | Sparinv Mix Høj Risiko KL A | SPIMHRKLA |
DK0060914901 | Sparinvest Mix Minimum Risiko KL A | SPIMIXMINRISKKLA |
Henvendelser vedrørende nærværende fondsbørsmeddelelse kan rettes til npa.pm@nykredit.dk cc jna@nykredit.dk
Med venlig hilsen
Dirk Schulze
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding
Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release
Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat
Dr. Sam Barrell CBE appointed as CEO of LifeArc19.4.2024 17:00:00 CEST | Press release
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam’s appointment follows an extensive international recruitment process. Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul Nurse. She joined the Crick in 2017 as Chief Operating Officer. Sam brings over 25 years of experience in the life science and healthcare sectors, and a wealth of knowledge of the activities in commercial, digital and health tech spaces which are critical to LifeArc’s strategy. She studied medicine, training as an anaesthetist and serving in General Practice for many years, and has held a number of senior leadership positions in the NHS, most recently as CEO of Taunton and Somerset NHS Foundation Trust. She